SCHEMBL6996806

SCHEMBL6996806

CC1=C(N)Nc2cc(C(=O)CCl)ccc2O1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
MAPT P10636 2/20 0.53
ALOX5 P09917 4/20 0.40
ATM Q13315 1/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
HTR7 P34969 1/20 0.37
HTR2B P41595 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
GSK3B P49841 2/20 0.36
NEK2 P51955 1/20 0.35
CTNNB1 P35222 1/20 0.35
WNT3A P56704 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6999811 0.89 ATM (0.47) ALDH1A1MAPTALOX5ATMKDM4E
SCHEMBL8113447 0.88 ALDH1A1 (0.43) ALDH1A1MAPTALOX5ATMKDM4E
SCHEMBL7002378 0.84 PKM (0.47) ALDH1A1MAPTALOX5KDM4ESMN1; SMN2
SCHEMBL6996551 0.78 ALDH1A1 (0.45) ALDH1A1MAPTALOX5KDM4ESMN1; SMN2
SCHEMBL1928583 0.76 ALOX5 (0.68) ALDH1A1MAPTALOX5KDM4EHTR7
SCHEMBL5670589 0.73 AHR (0.39) ALDH1A1MAPTSMN1; SMN2HTR7HTR2B
Hydrochloric Acid SCHEMBL5672533 0.72 AHR (0.38) MAPTSMN1; SMN2HTR7HTR2BKMT2A
SCHEMBL7000207 0.70 SMYD3 (0.58) ALDH1A1MAPTKDM4E
SCHEMBL532500 0.69 ALDH1A1 (1.00) ALDH1A1MAPTKDM4ESMN1; SMN2RXFP1
SCHEMBL29550875 0.69 ALDH1A1 (1.00) ALDH1A1MAPTKDM4ESMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed